BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...
Combination therapy
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...
Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors
Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China
China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...
FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC
US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...
Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...
Mirror Biologics and Merck KGaA Collaborate on Phase II Trial for Colorectal Cancer Immunotherapy
US-based Mirror Biologics, Inc., an off-the-shelf immunotherapy developer, has announced a clinical trial collaboration and...
Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products...
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...